8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
September 2004 in “Inpharma Weekly” August 2002 in “Inpharma Weekly” May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
5 citations
,
July 2003 in “Drug Development Research” Fluridil promotes hair growth safely and effectively for androgenetic alopecia.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.
December 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Flutamide, an oral anti-androgen therapy, is effective in treating female pattern hair loss, even without systemic androgen excess.
April 2022 in “Reactions Weekly”
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
42 citations
,
April 2011 in “Annals of Pharmacotherapy” Flutamide effectively treats female pattern hair loss with low doses showing good liver tolerance.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
August 2025 in “JAAD International” Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
6 citations
,
January 1996 in “Endocrine-related Cancer” Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.
5 citations
,
December 2014 in “Medicine and Pharmacy Reports” Ciproterone acetate improves hair regrowth and acne in most female patients.
1 citations
,
December 2011 in “Arzneimittelforschung” The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
July 2024 in “Reactions Weekly” January 2013 in “International journal of contemporary surgery” Using Cyproterone Acetate with Eflornithine together is safe and works better for treating facial hair in women.
June 2025 in “Experimental and Сlinical Urology” Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
September 2004 in “Evidencia actualizacion en la práctica ambulatoria” Using finasteride and doxazosina together works better for treating benign prostatic hyperplasia than using just one.
36 citations
,
November 1995 in “Clinical endocrinology” Low-dose flutamide helps reduce excessive hair growth and is even more effective with birth control, without bad effects on blood fats.
November 2025 in “Cochrane Database of Systematic Reviews” Cyproterone acetate works similarly to other treatments for hirsutism, but more research is needed.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.